Clinical Trial: Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07557914) titled 'Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study' on April 22.

Brief Summary: The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: HCC - Hepatocellular Carcinoma Diabetes

Intervention: DRU...